CLINXUS PARTNERSHIP DEVISES IMPROVED TESTS TO DETECT KIDNEY DAMAGE FOR NEW DRUGS IN DEVELOPMENT

[Source: Joe Gavan, ClinXus] – The Critical Path Institute (C-Path) Predictive Safety Testing Consortium (PSTC), which includes Grand Rapids-based ClinXus, has identified seven new tests to assess the safety of new drugs in development, specifically to monitor the drugs